Navigation Links
CMC Biologics Establishes Commercial Presence in Japan through Strategic Agreement with Innomedica
Date:9/12/2012

SEATTLE and TOKYO, Sept. 12, 2012 /PRNewswire/ -- CMC Biologics, a leading contract manufacturing organization known for its technical excellence in process development and cGMP manufacture, and Innomedica, a life sciences business development company specialized in Japan market, have entered into an agreement to facilitate CMC Biologics' customer base in the Japan market.

(Logo: http://photos.prnewswire.com/prnh/20110502/SF93356LOGO)

"We view this strategic agreement with Innomedica critical for us to serve our further growing customer base in the second largest healthcare market in the world," said Gustavo Mahler, Chief Operations Officer of CMC Biologics.  "Establishing an in-country commercial presence provides us with the necessary structure to localized services and communications for Japanese biotechnology and pharmaceutical customers for cGMP clinical and commercial production of biopharmaceuticals."

"We believe CMC Biologics is a great match for Japanese companies looking for premium quality biologics and flexible, committed partner with cGMP facilities in Europe and the USA," said Anna Kalmi of Innomedica.  "CMC has proven capability to carry out projects successfully, raising the clients' biologics development programs to the next level."

The Japanese market is the world's second largest healthcare system totaling $115 billion in biopharmaceutical sales and comprised of global biopharmaceutical leaders including Takeda, Otsuka, Astellas, Daiichi, Sankyo, Eisai and others. With a population of 130 million people with one of the highest GDPs in the world, the country has the fastest aging population of the seven major markets, all Japanese citizens are covered by health insurance, and as a result, high quality and innovative healthcare products are highly valued. 

About CMC Biologics

CMC Biologics is a leading contract development and manufacturing organization that provides fully integrated biopharmaceutical development and manufacturing solutions to clients around the world, from its facilities in Europe and the USA.  The Company has proven expertise in delivering custom solutions for the scale-up and cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials and in-market production.  The Company's wide range of integrated services includes cell line development, bioprocess development, formulation and comprehensive analytical testing.  Clients can also benefit from CMC Biologics' proprietary CHEF1® expression system for mammalian production.  CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers both fed-batch and perfusion production processes.  CMC Biologics is located in Copenhagen, Denmark, and Seattle, Washington. More detailed information can be found at www.cmcbiologics.com.

About Innomedica

Innomedica is a life sciences business development company specialized in Japan market. Innomedica has provided licensing, partnering and market entry services to European, Japanese and American pharmaceutical, medical technology and health product companies since 1997. The senior personnel in Innomedica's Tokyo, London and Helsinki offices are well connected and have a long track record in international strategic business development in life sciences. More detailed information can be found at www.innomedica.fi.  


'/>"/>
SOURCE CMC Biologics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
2. Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
3. Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
4. CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy
5. Avaxia Biologics Announces Appointment of Michael D. Rivard as VP Corporate Development
6. Chinese Compulsory Immunization Program for Livestock Creates Massive Opportunity for Animal Vaccines and Biologics Developers
7. CMC Biologics Achieves Successful Pre-Approval European GMP Inspection by MHRA for Commercial Manufacturing
8. Pinnacle Biologics and INTERmedic Medical Devices announce strategic manufacturing and distribution agreement for cancer laser technology
9. CMC Biologics Acquires XOMAs Bay Area Manufacturing Facility
10. Global Spinal Devices and Biologics Market 2011-2015
11. Synthetic Biologics Reports Second Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... , Dec. 9, 2016 aTyr Pharma, Inc. (Nasdaq: ... development of Physiocrine-based therapeutics to address severe, rare diseases, today announced ... upcoming BMO Prescriptions for Success Healthcare Conference at the InterContinental Barclay ... December 14, 2016, at 4:20 p.m. ET. About ... ...
(Date:12/9/2016)... , Dec. 9, 2016 Department of Health ... regulations for medical marijuana dispensaries under Act 16 are ... , and are now available online . ... in the plan for operation; process for dispensing medical ... well as where the dispensary facilities can be located," ...
(Date:12/8/2016)... VIEW, Calif. , Dec. 8, 2016 IRIDEX ... intends to offer newly issued shares of common stock, $0.01 ... pursuant to an underwritten public offering.  The final terms of ... the time of pricing, and there can be no assurance ... IRIDEX expects to use the net proceeds it ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical Institute ... The name change aligns the entire company with its existing Quality Insights ... , “We are very proud of the achievements associated with the West Virginia ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... 08, 2016 , ... Mirixa Corporation , a leading ... pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger to senior ... of sales. , Litsinger joined Mirixa in 2008 after serving as a ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... David ... with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, ... of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... development continuity to its innovative Unified Instance Manager architecture, meeting the needs ... this new version optimizes the unattended auto-dialing system without agents, Presence Robodialer, ...
Breaking Medicine News(10 mins):